Advisor Group Holdings, Inc. Myovant Sciences Ltd. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$24.03 - $27.02 $666,688 - $749,642	-27,744 Reduced 97.68%	659 $17,000
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $101,175 - $178,277	8,722 Added 44.32%	28,403 $509,000
Q2 2022 Aug 10, 2022	SELL	$7.78 - $14.69 $3,991 - $7,535	-513 Reduced 2.54%	19,681 $245,000
Q1 2022 May 04, 2022	BUY	$11.38 - $16.4 $9,786 - $14,103	860 Added 4.45%	20,194 $269,000
Q3 2021 Nov 05, 2021	SELL	$18.94 - $26.99 $15,758 - $22,455	-832 Reduced 4.13%	19,334 $433,000
Q2 2021 Aug 02, 2021	BUY	$17.07 - $24.56 $273,393 - $393,352	16,016 Added 385.93%	20,166 $459,000
Q1 2021 May 13, 2021	BUY	$20.46 - $25.18 $70,587 - $86,871	3,450 Added 492.86%	4,150 $85,000
Q4 2020 Feb 10, 2021	BUY	$13.8 - $27.62 $2,622 - $5,247	190 Added 37.25%	700 $19,000
Q3 2020 Nov 12, 2020	BUY	$14.05 - $22.6 $3,653 - $5,876	260 Added 104.0%	510 $7,000
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $1,835 - $5,210	250 New	250 $5,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.